Michelle Carr, Author at BioTuesdays

Developments

Zucara receives additional JDRF funding for Phase 2 study

Closely-held Zucara Therapeutics received an additional $2-million in funding from JDRF (Juvenile Diabetes Research Foundation) to support Zucara’s planned Phase 2a study of the effect of its ZT-01 on nocturnal...

June 15, 2023

Developments

FibroGen flunks Phase 3 in non-ambulatory DMD

FibroGen’s (NASDAQ: FGEN) Phase 3 LELANTOS-1 placebo-controlled trial of pamrevlumab for the treatment of non-ambulatory patients with Duchenne muscular dystrophy (DMD) on background corticosteroids did not meet the...

June 8, 2023

Developments

Vistagen posts positive Phase 2A study in women with menopausal hot flashes

Vistagen (NASDAQ:VTGN) reported that PH80, one of the company’s five investigational neuroactive nasal sprays, demonstrated statistically significant efficacy versus placebo in an exploratory Phase 2A study for the...

June 7, 2023

Markets

Research Capital ups Profound Medical to speculative buy; PT to $17.25

Research Capital upgraded Profound Medical (NASDAQ:PROF; TSX:PRN) to “speculative buy” from “hold” and raised its price target to $17.25 from $10.90, after the AMA approved three new Category 1 CPT codes for prostate...

June 5, 2023

Developments

Synlogic initiates pivotal study for phenylketonuria

Synlogic (NASDAQ:SYBX) initiated Synpheny-3, a global, Phase 3 study evaluating the efficacy and safety of SYNB1934 as a potential treatment for phenylketonuria (PKU), a rare inherited disorder that causes an amino...

June 5, 2023

Developments

AMA unveils new CPT Category 1 codes for Profound Medical’s TULSA-PRO

Profound Medical (NASDAQ:PROF; TSX:PRN) announced that, with sponsorship and support from multiple physician specialty societies, it has received from the American Medical Association (AMA) three new Current Procedural...

June 2, 2023

Executive Moves

Ondine Biomedical names Simon Sinclair as CMO

Ondine Biomedical (LON:OBI) appointed Simon Sinclair, M.D., Ph.D., as chief medical officer, as the company prepares to start a U.S. Phase 3 trial of its nasal photodisinfection technology. Dr. Sinclair has more than 20...

June 1, 2023

Developments

Ionis posts late-stage clinical progress in HAE

Ionis Pharmaceuticals (NASDAQ:IONS) reported positive clinical progress with donidalorsen, its late-stage investigational prophylactic therapy for hereditary angioedema (HAE). Topline two-year open-label extension (OLE)...

June 1, 2023

Developments

Glyscend posts positive topline Phase 2a results for Type 2 diabetes and obesity

Closely-held Glyscend Therapeutics reported that Phase 1 and Phase 2a clinical trials demonstrated that the novel mechanism of its lead candidate, GLY-200, offers significant and clinically relevant reductions in...

May 31, 2023

Developments

Profound to reveal interim 5-year TACT follow-up data during June 6th webinar

Profound Medical (NASDAQ:PROF; TSX:PRN) will unveil interim five-year follow-up data from its TACT (TULSA-PRO ablation clinical trial) pivotal study at a live webinar event it is hosting on June 6 at 6 pm ET. The...

May 30, 2023

Author - Michelle Carr

Zucara receives additional JDRF funding for Phase 2 study

FibroGen flunks Phase 3 in non-ambulatory DMD

Vistagen posts positive Phase 2A study in women with menopausal hot flashes

Research Capital ups Profound Medical to speculative buy; PT to $17.25

Synlogic initiates pivotal study for phenylketonuria

AMA unveils new CPT Category 1 codes for Profound Medical’s TULSA-PRO

Ondine Biomedical names Simon Sinclair as CMO

Ionis posts late-stage clinical progress in HAE

Glyscend posts positive topline Phase 2a results for Type 2 diabetes and obesity

Profound to reveal interim 5-year TACT follow-up data during June 6th webinar

Subscribe